Adaptive Biotechnologies EBITDA Margin 2018-2021 | ADPT

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Adaptive Biotechnologies (ADPT) over the last 10 years. The current EBITDA margin for Adaptive Biotechnologies as of September 30, 2021 is .
Adaptive Biotechnologies EBITDA Margin Historical Data
2021-09-30 $0.15B $-0.17B -119.18%
2021-06-30 $0.13B $-0.16B -118.80%
2021-03-31 $0.12B $-0.15B -128.70%
2020-12-31 $0.10B $-0.14B -146.94%
2020-09-30 $0.09B $-0.13B -136.96%
2020-06-30 $0.09B $-0.11B -118.48%
2020-03-31 $0.09B $-0.09B -96.77%
2019-12-31 $0.09B $-0.08B -89.41%
2019-06-30 $0.05B $-0.04B -82.69%
2019-03-31 $0.04B $-0.04B -95.24%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.761B $0.098B
Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95